ACRP Features Schulman IRB Biosafety Officer
February 2nd, 2017
Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP, Biosafety Officer at Schulman IRB, discusses the emphasis on biosafety in clinical trials in an ACRP article. Since the approval of gene therapies by the U.S. Food and Drug Administration, Eisenman notes, “the climate is right for advances in clinical trials involving human gene transfer, particularly for oncology research.”
Read the full article here.